Reprieve Cardiovascular

About Reprieve Cardiovascular

Reprieve Cardiovascular offers the Reprieve System, a personalized intelligent decongestion management solution that utilizes real-time patient data to optimize diuretic therapy for acute decompensated heart failure patients. This system addresses the challenge of fluid overload, which accounts for 83% of heart failure hospitalizations, by providing physicians with enhanced visibility and control over treatment decisions.

```xml <problem> Fluid overload is a primary driver of hospitalizations for acute decompensated heart failure (ADHF) patients, yet current diuretic-based treatments lack the precision needed to safely and effectively manage fluid removal. Physicians often lack real-time feedback on individual patient response, making it difficult to balance fluid removal with the risk of kidney injury. </problem> <solution> Reprieve Cardiovascular offers the Reprieve System, a personalized intelligent decongestion management (IDM) solution designed for ADHF patients. The system leverages real-time patient data and a novel approach to diuretic management, providing physicians with enhanced visibility and control over therapy throughout treatment. By combining proven technology with continuous monitoring, the Reprieve System aims to safely accelerate fluid removal, optimizing diuretic therapy and potentially reducing hospital stays. The system provides care teams with the information needed to make efficient, data-driven treatment decisions. </solution> <features> - Real-time patient data integration for personalized diuretic management. - Continuous monitoring of patient response to diuretic therapy. - Intelligent algorithms to optimize fluid removal rates. - Enhanced visibility and control of therapy for physicians and care teams. - Aims to safely accelerate fluid removal compared to standard diuretic administration. </features> <target_audience> The primary target audience includes physicians, care teams, and hospitals involved in the treatment of acute decompensated heart failure patients. </target_audience> ```

What does Reprieve Cardiovascular do?

Reprieve Cardiovascular offers the Reprieve System, a personalized intelligent decongestion management solution that utilizes real-time patient data to optimize diuretic therapy for acute decompensated heart failure patients. This system addresses the challenge of fluid overload, which accounts for 83% of heart failure hospitalizations, by providing physicians with enhanced visibility and control over treatment decisions.

Where is Reprieve Cardiovascular located?

Reprieve Cardiovascular is based in Milford, United States.

When was Reprieve Cardiovascular founded?

Reprieve Cardiovascular was founded in 2018.

How much funding has Reprieve Cardiovascular raised?

Reprieve Cardiovascular has raised 47050000.

Location
Milford, United States
Founded
2018
Funding
47050000
Employees
23 employees
Major Investors
Sante Ventures, Lightstone Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

Reprieve Cardiovascular

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Reprieve Cardiovascular offers the Reprieve System, a personalized intelligent decongestion management solution that utilizes real-time patient data to optimize diuretic therapy for acute decompensated heart failure patients. This system addresses the challenge of fluid overload, which accounts for 83% of heart failure hospitalizations, by providing physicians with enhanced visibility and control over treatment decisions.

reprievecardio.com2K+
cb
Crunchbase
Founded 2018Milford, United States

Funding

$

Estimated Funding

$20M+

Major Investors

Sante Ventures, Lightstone Ventures

Team (20+)

No team information available.

Company Description

Problem

Fluid overload is a primary driver of hospitalizations for acute decompensated heart failure (ADHF) patients, yet current diuretic-based treatments lack the precision needed to safely and effectively manage fluid removal. Physicians often lack real-time feedback on individual patient response, making it difficult to balance fluid removal with the risk of kidney injury.

Solution

Reprieve Cardiovascular offers the Reprieve System, a personalized intelligent decongestion management (IDM) solution designed for ADHF patients. The system leverages real-time patient data and a novel approach to diuretic management, providing physicians with enhanced visibility and control over therapy throughout treatment. By combining proven technology with continuous monitoring, the Reprieve System aims to safely accelerate fluid removal, optimizing diuretic therapy and potentially reducing hospital stays. The system provides care teams with the information needed to make efficient, data-driven treatment decisions.

Features

Real-time patient data integration for personalized diuretic management.

Continuous monitoring of patient response to diuretic therapy.

Intelligent algorithms to optimize fluid removal rates.

Enhanced visibility and control of therapy for physicians and care teams.

Aims to safely accelerate fluid removal compared to standard diuretic administration.

Target Audience

The primary target audience includes physicians, care teams, and hospitals involved in the treatment of acute decompensated heart failure patients.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.